Pharmaceuticals

Cosentyx Drug Market Outlook 2026–2030: Key Business Drivers and Trends

March 5, 2026March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cosentyx drug market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Cosentyx Drug Market between 2026 and 2030?

The cosentyx drug market size has seen substantial growth recently. It is anticipated to expand from $5.68 million in 2025 to $6.21 million in 2026, exhibiting a compound annual growth rate (CAGR) of 9.2%. This historical period’s growth can be linked to the approval of il 17 inhibitors, the high prevalence of psoriasis and arthritis, limited response to tnf inhibitors, specialist dermatology adoption, and biologic treatment guidelines.

The market size for the Cosentyx drug is anticipated to experience substantial growth over the next few years. It is projected to expand to $8.74 million by 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. This projected expansion can be attributed to an increase in the diagnosis of autoimmune diseases, the broadening of treatment indications, rising patient awareness, improved accessibility to biologic therapies, and supporting data on long-term efficacy. Significant trends influencing this period include the increasing adoption of IL-17 inhibitor therapies, a wider application across various autoimmune indications, a shift towards targeted biologic treatments, a greater emphasis on long-term maintenance therapy, and a growing demand for self-injectable biologics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19891&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Cosentyx Drug Market?

The growing occurrence of autoimmune conditions is anticipated to fuel the expansion of the cosentyx market in the future. Autoimmune diseases are disorders where the immune system erroneously targets the body’s healthy cells and tissues. This rise in prevalence is linked to genetic susceptibility, environmental elements like infections and pollutants, and lifestyle shifts such as increased stress and dietary changes. Cosentyx (secukinumab) assists patients with autoimmune diseases by targeting and blocking interleukin-17A, a crucial cytokine involved in inflammation, thereby alleviating symptoms, enhancing quality of life, and effectively managing conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis. For example, in August 2024, data from Public Health Scotland, a Scotland-based national organization, indicated that in 2023, the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients. Thus, the increasing prevalence of autoimmune diseases propels the cosentyx market. Cosentyx Drug Market Driver: Rising Healthcare Expenditure Expected To Enhance Cosentyx Drug

What Segments Are Included Within The Cosentyx Drug Market?

The cosentyx drug market covered in this report is segmented –

1) By Indication: Hidradenitis suppurativa, Psoriatic arthritis, Ankylosing spondylitis, Plaque Psoriasis

2) By Route Of Administration: Subcutaneous injection, Intravenous infusion

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Which Trends Are Expected To Influence The Cosentyx Drug Market In The Upcoming Years?

Key companies operating within the cosentyx drug market are focusing their efforts on developing sophisticated therapies, including biological treatment options. Their aims are to address outstanding medical needs, boost treatment effectiveness, and deliver targeted therapies for managing persistent autoimmune conditions, thereby enhancing their market standing and serving a growing patient base. Biologic treatments are advanced therapies derived from living organisms or their cells that specifically target components of the immune system, such as interleukin-17A, to regulate inflammatory responses and effectively treat autoimmune conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, in October 2023, Novartis AG, a pharmaceutical company based in Switzerland, obtained FDA approval for Cosentyx (secukinumab) as the first new biologic treatment option for moderate to severe hidradenitis suppurativa (HS) in nearly a decade. This approval represents a significant step forward in the treatment landscape for HS, a chronic and often debilitating skin condition marked by painful lumps that can lead to scarring and psychological distress.

Who Are The Major Companies Operating In The Cosentyx Drug Market?

Major companies operating in the cosentyx drug market are Novartis AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cosentyx-drug-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Cosentyx Drug Market?

North America was the largest region in the cosentyx drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cosentyx drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cosentyx Drug Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19891&type=smp

Browse Through More Reports Similar to the Global Cosentyx Drug Market 2026, By The Business Research Company

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Pharmaceuticals Market 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Pharmaceutical Label Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-label-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795